Author Archives: Patricia Inacio, PhD

Polysplenia Syndrome a Risk Factor for Early PH, Study Suggests

People with polysplenia syndrome — a condition characterized by a “left-sidedness” on both sides of the body — have an increased risk for early development of pulmonary hypertension (PH), a Japanese study suggests. The study, titled “Polysplenia Syndrome as a Risk Factor for Early Progression of Pulmonary Hypertension,” was…

Repeated Measurements of Biomarkers May Improve Prognostic Accuracy in PAH-CHD Patients, Study Finds

Repeated measurements of different biomarkers over time offer a better risk prediction than single measurements for pulmonary arterial hypertension (PAH) associated with congenital heart disease, a study reports. The study, “Prognostic value of multiple repeated biomarkers in pulmonary arterial hypertension associated with congenital heart disease,” was published in…

Genetic Variants Near Two Genes Linked to PAH Risk, Large Study Reports

Genetic variants close to the SOX17 and the HLA-DPB1 genes are linked to pulmonary arterial hypertension (PAH), according to the findings of the largest genetic study to date in PAH patients. The study, “Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis,” was published in the…

Adempas Seen to Benefit Idiopathic PAH Patients Who Fail to Respond to Revatio in Pilot Study

Idiopathic pulmonary arterial hypertension (IPAH) patients who failed to respond to treatment with Revatio (sildenafil), either alone or combined with other phosphodiesterase type 5 inhibitors, may benefit by switching to Adempas (riociguat), according to results of a pilot study. Adempas was also seen to ably help treatment-naive patients, using it as a first…

Higher Concentration of Inhaled Ventavis May Help PAH Patients Stick to Treatment, Study Suggests

More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment administration, an observational study reports. The study looked at the inhalation behavior of PAH patients who were switched from…

Treatment with Milrinone Improves Heart Function in Patients with PH Due to Left Heart Disease, Study Finds

Intravenous treatment with the approved heart failure medicine milrinone leads to significant improvements in heart structure and function in patients with mild-to-moderate pulmonary hypertension (PH) due to left heart disease, a study has found.” The report titled “Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients…